Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network

被引:233
|
作者
Tiemann, M
Schrader, C
Klapper, W
Dreyling, MH
Campo, E
Norton, A
Berger, F
Kluin, P
Ott, G
Pileri, S
Pedrinis, E
Feller, AC
Merz, H
Janssen, D
Hansmann, ML
van Krieken, H
Möller, P
Stein, H
Unterhalt, M
Hiddemann, W
Parwaresch, R
机构
[1] Univ Hosp Schleswig Holstein, Dept Haematol, D-24116 Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Dept Haematopathol, D-24116 Kiel, Germany
[3] Univ Hosp Schleswig Holstein, Lymph Node Registry, D-24116 Kiel, Germany
[4] Univ Munich, Div Med 3, Munich, Germany
[5] Dept Haematopathol, Barcelona, Spain
[6] Barts & London NHS Trust, Dept Histopathol, London, England
[7] Ctr Hosp Lyon Sud, Dept Pathol, F-69310 Pierre Benite, France
[8] Leiden Univ, Dept Pathol, Leiden, Netherlands
[9] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[10] Univ Bologna, Bologna, Italy
[11] Dept Pathol, Locarno, Switzerland
[12] Univ Hosp Schleswig Holstein, Dept Pathol, Lubeck, Germany
[13] Goethe Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany
[14] Univ Nijmegen, Dept Pathol, Nijmegen, Netherlands
[15] Univ Ulm, Dept Pathol, Ulm, Germany
[16] Univ Berlin, Dept Pathol, Berlin, Germany
关键词
mantle cell lymphoma; cytology; growth pattern; Ki-67; index; mitotic index;
D O I
10.1111/j.1365-2141.2005.05716.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mantle cell lymphoma (MCL) is a distinct lymphoma subtype with a particularly poor clinical outcome. The clinical relevance of the morphological characteristics of these tumours remains uncertain. The European MCL Network reviewed 304 cases of MCL to determine the prognostic significance of histopathological characteristics. Cytomorphological subtypes, growth pattern and markers of proliferation (mitotic and Ki-67 indices) were analysed. In addition to the known cytological subtypes, classical (87.5%), small cell (3.6%), pleomorphic (5.9%) and blastic (2.6%), we identified new pleomorphic subgroups with mixtures of cells (classical + pleomorphic type; 1.6%) or transitions (classical/pleomorphic type; 1.6%), which, however, did not differ significantly in overall survival time. Exactly 80.5% of cases displayed a diffuse growth pattern, whereas 19.5% of cases had a nodular growth pattern, which was associated with a slightly more favourable prognosis. A high proliferation rate (mitotic or Ki-67 indices) was associated with shorter overall survival. Cut-off levels were defined that allowed three subgroups with different proliferation rates to be discriminated, which showed significantly different clinical outcomes (P < 0.0001). Based on this large clinicopathological study of prospective clinical trials, multivariate analysis confirmed the central prognostic role of cell proliferation and its superiority to all other histomorphological and clinical criteria.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 50 条
  • [31] "In Situ" Mantle Cell Lymphoma (MCL), an Incidental Finding with an Indolent Clinical Course.
    Carvajal, A.
    Sua, L.
    Silva, N.
    Pittaluga, S.
    Royo, C.
    Sargent, R. L.
    Climent, F.
    Jacobs, S. A.
    Delabie, J.
    Naresh, K.
    Bagg, A.
    Harris, N. L.
    Swerdlow, S. H.
    Jaffe, E. S.
    Campo, E.
    MODERN PATHOLOGY, 2011, 24 : 289A - 289A
  • [32] Gastrointestinal involvement in mantle cell lymphoma (MCL).: A prospective clinical, endoscopical, pathological and molecular study.
    Salar, A
    Juanpere, N
    Gonzalez-Barca, E
    Bellosillo, B
    Espinet, B
    Seoane, A
    Panadés, A
    Romagosa, V
    Pedro, C
    Nieto, M
    Abella, E
    Domingo-Domenech, E
    Sole, F
    Fernandez-Sevilla, A
    Besses, C
    Serrano, S
    BLOOD, 2005, 106 (11) : 246B - 246B
  • [33] Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era
    Chiappella, Annalisa
    Puccini, Benedetta
    Rossi, Marianna
    Ferrero, Simone
    Arcaini, Luca
    Audisio, Ernesta
    Baldi, Ileana
    Boccomini, Carola
    Botto, Barbara
    Alberto, Fabbri
    Frairia, Chiara
    Freilone, Roberto
    Ladetto, Marco
    Novero, Domenico
    Paulli, Marco
    Pregno, Patrizia
    Priolo, Giorgio
    Rigacci, Luigi
    Vitolo, Umberto
    BLOOD, 2009, 114 (22) : 1144 - 1144
  • [34] European intergroup study on mantle cell lymphoma: Pathology, proliferation indices and survival.
    Kluin, PM
    BLOOD, 1998, 92 (10) : 85A - 85A
  • [35] Comprehensive genomic analysis in Mantle Cell Lymphoma identifies risk factors and predicts patients' outcome: results from the EU-MCL network trials
    Khouja, M.
    Jiang, L.
    Regmi, B.
    Pal, K.
    Stewart, P.
    Dreyling, M.
    Darzentas, N.
    Hoster, E.
    de Castro, Gonzalez D.
    Pott, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 22 - 22
  • [36] SYSTEMATIC REVIEW AND ASSESSMENT OF OUTCOMES IN PATIENTS WITH THE RARE DISEASE OF MANTLE CELL LYMPHOMA (MCL)
    Gaudig, M.
    Erhardt, W.
    Kempel, A.
    VALUE IN HEALTH, 2014, 17 (03) : A96 - A96
  • [37] TP53 Gene Mutations in Russian Patients With Mantle Cell Lymphoma (MCL)
    Biderman, Bella
    Koroleva, Darya
    Severina, Natalya
    Gabeeva, Nelly
    Julhakyan, Hunan
    Zvonkov, Evgeniy
    Sudarikov, Andrey
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S460 - S460
  • [38] Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study.
    Goy, A
    Bernstein, S
    Kahl, B
    Epner, E
    Leonard, JP
    Stadtmauer, E
    Morgan, D
    Belt, R
    Baidas, S
    Fisher, RI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
  • [39] IBRORS-MCL Study: A Spanish Retrospective and Observational Study of Relapsed/Refractory Mantle-Cell Lymphoma (MCL) Treated with Ibrutinib in Routine Clinical Practice
    Manuel Sancho, Juan
    Marin, Ana
    Fernandez, Silvia
    Javier Capote, Francisco
    Canigral, Carolina
    Grande, Carlos
    Donato, Eva
    Zeberio, Izaskun
    Manuel Puerta, Jose
    Rivas, Alfredo
    Perez Ceballos, Elena
    Vale, Ana
    Martin, Alejandro
    Salar, Antonio
    Gonzalez Barca, Eva
    Teruel, Anabel
    Pastoriza, Carmen
    Conde Royo, Diego
    Sanchez, Joaquin
    Barrenetxea, Cristina
    Arranz, Reyes
    Hernandez Rivas, Jose Angel
    Ramirez, Josefa
    Jimenez, Aroa
    Loriente, Cristina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S258 - S259
  • [40] Bystander-based immunotherapy for patients with mantle cell lymphoma (MCL): Proof of principle
    Dessureault, Sophie
    Noyes, David
    Tao, Jianguo
    Moscinski, Lynn
    Schell, Michael
    Antonia, Scott J.
    Sotomayor, Eduardo M.
    BLOOD, 2007, 110 (11) : 192B - 192B